Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
21 results
D2.283 - Efficacy and safety of remibrutinib in adults with IgE-mediated peanut allergy: A Phase 2 study
D2.286 - High Prevalence of Clinical Tolerance to Avoided Foods in LTP-Sensitized Patients
D2.287 - Clinical characterization and predictors of diagnosis and severity in sunflower seed allergy in a pediatric population
D2.276 - Clinical and Immunological Differences in Shellfish Allergy
D2.278 - Dose-response analysis of remibrutinib in oral food challenge outcomes among adults with IgE-mediated peanut allergy
D2.280 - Biphasic anaphylaxis due to psyllium (Plantago ovata) allergy, the primary component of a plant-based sausage
D2.281 - Ensemble Immunoinformatic Prediction Reveals Novel Allergen Candidates in Nigella sativa Seeds and Oil
D2.284 - Peanut Materials Used for Immunoassay Calibration Exhibit Distinct Allergen Profiles
D2.285 - Baked egg oral Immunotherapy as an alternative in patients who failed raw egg oral immunotherapy
D2.545 - Perception of adult patients in an allergy clinic after using Scribe artificial intelligence, our experience
D2.546 - Ethical Impact of Generative AI in Clinical Practice for Asthma and Allergy
D2.547 - The Transparent and Credible AI for Clinical Protocols
D2.548 - Expert Evaluation of Dialogue Quality and Clinical Reasoning in a Hybrid Multilingual LLM–Algorithm Allergy Decision-Support System: A Pilot Study of 34 Real-World Cases
D3.419 - Efficacy, safety, and remission outcomes of omalizumab in elderly patients with severe allergic asthma: a subgroup analysis by age of onset
D3.420 - Real-world epidemiologic characteristics of patients treated with dupilumab for type 2 inflammatory indications: a single-center retrospective cohort study
D3.422 - Dupilumab in children with multimorbid atopic phenotype: therapy efficacy, safety and biomarker changes
D3.424 - Retrospective Analysis of Self-Administration of Biologic Treatments for Severe Asthma and Chronic Urticaria
D3.426 - Predicting response to omalizumab in patients with chronic spontaneous urticaria: The first results of the global multicenter UCARE SCOPUS project
D3.427 - Challenging the paradigm: Use of omalizumab in refractory angioedema in a 2-year-old child
D3.428 - Substratification of Biologic Treatment Using Dupilumab in Eosinophilic COPD
Pagination
Current page
1
Page
2
Next page
Next
Last page
Last
Download the app
The congress at your fingertips
Available on
Download